Investor Presentation Q1 FY 27

Investor Presentation - Q1FY27 - Revenue ₹841 cr +35.6% YoY; EBITDA ₹213 cr +112.8%; PAT ₹159 cr +173.9% - UK & Europe revenue ₹356 cr +74.7% YoY; Europe emerging as key growth engine with QliniQ acquisition contributing ₹44 cr - EBITDA margin expanded 919 bps YoY to 25.3%, driven by gross margin and operating leverage - Cash balance strong at ₹1,058 cr; net cash ₹1,031 cr supports organic and inorganic growth - US revenue ₹377 cr +15.1% YoY; Australia & NZ ₹88 cr +53.7% YoY; RoW ₹20 cr -36.8% YoY - Strategic focus on OTC segment growth, capacity expansion to 16 bn units p.a., and calibrated acquisitions - R&D investment at ₹23.2 cr (2.8% of revenue) with 200+ products in pipeline - India Ratings revised outlook to Positive; strong credit ratings maintained - Management targets broad-based growth, margin expansion, and European platform strengthening